España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Outlook Therapeutics
OTLK
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$6.28
-0.07
-1.10%
Last update: 4:52 PM
15 minutes delayed
Get Report
Comment
Outlook Therapeutics (OTLK) Forecast
News
Earnings
Outlook Therapeutics (OTLK) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Outlook Therapeutics (NASDAQ:OTLK) Stock
Outlook Therapeutics Stock (NASDAQ: OTLK)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, October 18, 2024
BTIG Reiterates Buy on Outlook Therapeutics, ...
Benzinga Newsdesk
Thursday, October 03, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
Wednesday, September 04, 2024
Outlook Therapeutics Completes Enrollment For...
Benzinga Newsdesk
Tuesday, September 03, 2024
Ascendiant Capital Maintains Buy on Outlook T...
Benzinga Newsdesk
Thursday, August 15, 2024
HC Wainwright & Co. Reiterates Buy on Outlook...
Benzinga Newsdesk
Wednesday, August 14, 2024
Outlook Therapeutics Says Resubmission Of ONS...
Benzinga Newsdesk
Outlook Therapeutics Q3 2024 Adj EPS $(0.83) ...
Benzinga Newsdesk
Monday, July 08, 2024
Outlook Therapeutics Secures UK MHRA Marketin...
Benzinga Newsdesk
Tuesday, May 28, 2024
Outlook Therapeutics Gains Marketing Authoriz...
Benzinga Newsdesk
Friday, May 17, 2024
HC Wainwright & Co. Reiterates Buy on Outlook...
Benzinga Newsdesk
Wednesday, May 15, 2024
Outlook Therapeutics Q2 2024 Adj EPS $(1.55) ...
Benzinga Newsdesk
Monday, May 13, 2024
Outlook Therapeutics Submits Marketing Author...
Benzinga Newsdesk
Thursday, May 02, 2024
Outlook Therapeutics To Present At Retina Wor...
Benzinga Newsdesk
Friday, April 12, 2024
Outlook Therapeutics Files Prospectus Supplem...
Benzinga Newsdesk
Monday, April 01, 2024
Insiders Buying Outlook Therapeutics And 2 Other Stocks
Avi Kapoor
Thursday, March 28, 2024
Tang Capital Partners Discloses 9.99% Passive...
Benzinga Newsdesk
Wednesday, March 27, 2024
Outlook Therapeutics shares are trading highe...
Benzinga Newsdesk
BTIG Upgrades Outlook Therapeutics to Buy, An...
Benzinga Newsdesk
Monday, March 25, 2024
HC Wainwright & Co. Maintains Buy on Outlook ...
Benzinga Newsdesk
Friday, March 22, 2024
Gold Moves Lower; Lululemon Shares Plummet
Avi Kapoor
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Dow Dips 200 Points; Nike Shares Fall After Q3 Results
Avi Kapoor
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?
Vandana Singh
Outlook Therapeutics shares are trading highe...
Benzinga Newsdesk
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
Market-Moving News for March 22nd
Benzinga Newsdesk
On 21 March 2024, EU's CHMP Adopted A Positive Opinion, Recommending The Granting Of A Marketing Authorization For Outlook Therapeutics' Lytenava, Intended For Treatment Of Neovascular Age-related Macular Degeneration
Charles Gross
Thursday, March 14, 2024
Trading Halt: Halt status updated at 8:55:00 ...
Benzinga Newsdesk
Wednesday, March 13, 2024
Trading Halt: Halted at 7:50:00 p.m. ET - Tra...
Benzinga Newsdesk
Tuesday, March 12, 2024
Outlook Therapeutics Announces 1-for-20 Rever...
Benzinga Newsdesk
Over $1.7M Bet On Globalstar? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Avi Kapoor
Thursday, February 22, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
Thursday, February 15, 2024
Chardan Capital Upgrades Outlook Therapeutics...
Benzinga Newsdesk
Wednesday, February 14, 2024
Outlook Therapeutics Provides Corporate Updat...
Benzinga Newsdesk
Outlook Therapeutics Q1 2024 GAAP EPS $(0.04)...
Benzinga Newsdesk
Wednesday, January 31, 2024
Outlook Therapeutics Doses Subject For NORSE ...
Benzinga Newsdesk
Thursday, January 25, 2024
Guggenheim Upgrades Outlook Therapeutics to B...
Benzinga Newsdesk
Brookline Capital Upgrades Outlook Therapeuti...
Benzinga Newsdesk
Tuesday, January 23, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
Outlook Therapeutics shares are trading highe...
Benzinga Newsdesk
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
Outlook Therapeutics Announced Private Placem...
Benzinga Newsdesk
Outlook Therapeutics Announces FDA Agreement ...
Benzinga Newsdesk
Friday, December 29, 2023
Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
Ascendiant Capital Maintains Buy on Outlook T...
Benzinga Newsdesk
Wednesday, December 27, 2023
Capital One Upgrades Outlook Therapeutics to ...
Benzinga Newsdesk
Friday, December 22, 2023
Outlook Therapeutics Clocks FY23 EPS Loss of ...
Benzinga Newsdesk
Tuesday, December 19, 2023
Outlook Therapeutics Submits Special Protocol...
Benzinga Newsdesk
Wednesday, December 06, 2023
Outlook Therapeutics Announces Realignment Of...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch